

970

WHO Technical Report Series

970

WHO Expert Committee on Specifications for Pharmaceutical Preparations • WHO Technical Report Series

The Expert Committee on Specifications for Pharmaceutical Preparations works towards clear, independent and practical standards and guidelines for the quality assurance of medicines. Standards are developed by the Committee through worldwide consultation and an international consensus-building process. The following new guidelines were adopted and recommended for use: Development of monographs for *The International Pharmacopoeia*; WHO good manufacturing practices: water for pharmaceutical use; Pharmaceutical development of multisource (generic) pharmaceutical products – points to consider; Guidelines on submission of documentation for a multisource (generic) finished pharmaceutical product for the WHO Prequalification of Medicines Programme: quality part; Development of paediatric medicines: points to consider in formulation; Recommendations for quality requirements for artemisinin as a starting material in the production of antimalarial active pharmaceutical ingredients.

# WHO Expert Committee on Specifications for Pharmaceutical Preparations

Forty-sixth report



## SELECTED WHO PUBLICATIONS OF RELATED INTEREST

---

The World Health Organization was established in 1948 as a specialized agency of the United Nations serving as the directing and coordinating authority for international health matters and public health. One of WHO's constitutional functions is to provide objective and reliable information and advice in the field of human health, a responsibility that it fulfils in part through its extensive programme of publications. The Organization seeks through its publications to support national health strategies and address the most pressing public health concerns of populations around the world. To respond to the needs of Member States at all levels of development, WHO publishes practical manuals, handbooks and training material for specific categories of health workers; internationally applicable guidelines and standards; reviews and analyses of health policies, programmes and research; and state-of-the-art consensus reports that offer technical advice and recommendations for decision-makers. These books are closely tied to the Organization's priority activities, encompassing disease prevention and control, the development of equitable health systems based on primary health care, and health promotion for individuals and communities. Progress towards better health for all also demands the global dissemination and exchange of information that draws on the knowledge and experience of all WHO's Member countries and the collaboration of world leaders in public health and the biomedical sciences. To ensure the widest possible availability of authoritative information and guidance on health matters, WHO secures the broad international distribution of its publications and encourages their translation and adaptation. By helping to promote and protect health and prevent and control disease throughout the world, WHO's books contribute to achieving the Organization's principal objective — the attainment by all people of the highest possible level of health.

The WHO Technical Report Series makes available the findings of various international groups of experts that provide WHO with the latest scientific and technical advice on a broad range of medical and public health subjects. Members of such expert groups serve without remuneration in their personal capacities rather than as representatives of governments or other bodies; their views do not necessarily reflect the decisions or the stated policy of WHO. An annual subscription to this series, comprising about four to six such reports, costs CHF 150.00/US\$ 180.00 (CHF 105.00/US\$ 126.00 in developing countries). For further information, please contact: WHO Press, World Health Organization, 20 avenue Appia, 1211 Geneva 27, Switzerland (tel. +41 22 791 3264; fax: +41 22 791 4857; e-mail: [bookorders@who.int](mailto:bookorders@who.int); order on line: <http://www.who.int/bookorders>).

### **The International Pharmacopoeia**, fourth edition.

Volume 1: general notices; monographs for pharmaceutical substances (A–O)

Volume 2: monographs for pharmaceutical substances (P–Z); monographs for dosage forms and radiopharmaceutical preparations; methods of analysis; reagents.

2006 (1500 pages), also available on CD-ROM and online

First supplement: general notices; monographs for pharmaceutical substances; monographs for dosage forms; general and specific monographs; methods of analysis; International Chemical Reference Substances; International Infrared Reference Spectra; reagents, test solutions and volumetric solutions.

2008 (309 pages), also available on CD-ROM and online

Second supplement: general notices; monographs for pharmaceutical substances and radiopharmaceuticals; monographs for dosage forms; general and specific monographs; methods of analysis; International Chemical Reference Substances; International Infrared Reference Spectra; reagents, test solutions and volumetric solutions.

2011 (CD-ROM and online)

### **Basic tests for drugs: pharmaceutical substances, medicinal plant materials and dosage forms**

1998 (94 pages)

### **Basic tests for pharmaceutical dosage forms**

1991 (134 pages)

### **Quality Assurance of Pharmaceuticals: a compendium of guidelines and related materials**

Updated, comprehensive edition, 2011 (CD-ROM and online)

Also available on: WHO training modules on GMP. A resource and study pack for trainers, 2007 (CD-ROM).

### **WHO Expert Committee on Specifications for Pharmaceutical Preparations**

Forty-fifth report.

WHO Technical Report Series, No. 961, 2011 (428 pages)

### **International Nonproprietary Names (INN) for pharmaceutical substances**

Cumulative List No. 14

2011 (available on CD-ROM only)

### **The selection and use of essential medicines**

Report of the WHO Expert Committee (including the Model List of Essential Medicines for Children).

WHO Technical Report Series, No. 965, 2011 (249 pages)

W H O T e c h n i c a l R e p o r t S e r i e s  
9 7 0

# WHO Expert Committee on Specifications for Pharmaceutical Preparations

---

Forty-sixth report

*This report contains the collective views of an international group of experts and does not necessarily represent the decisions or the stated policy of the World Health Organization*



**World Health  
Organization**

WHO Library Cataloguing-in-Publication Data

Forty-sixth report of the WHO Expert Committee on specifications for pharmaceutical preparations.

(WHO technical report series ; no. 970)

1.Pharmaceutical preparations - standards. 2.Technology, Pharmaceutical - standards. 3. Drug industry - legislation. 4.Quality control. I.World Health Organization. II.Series.

ISBN 978 92 4 120970 0

(NLM classification: QV 771)

ISSN 0512-3054

© World Health Organization 2012

All rights reserved. Publications of the World Health Organization are available on the WHO web site ([www.who.int](http://www.who.int)) or can be purchased from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: [bookorders@who.int](mailto:bookorders@who.int)). Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to WHO Press through the WHO web site ([http://www.who.int/about/licensing/copyright\\_form/en/index.html](http://www.who.int/about/licensing/copyright_form/en/index.html)).

The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by the World Health Organization to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use.

This publication contains the collective views of an international group of experts and does not necessarily represent the decisions or the policies of the World Health Organization.

Design: WHO/WHP (Sophie Guetaneh Aguettant)

Layout: Cristina Ortiz (El Salvador)

Printed in Italy

# Contents

<b>1. Introduction</b>	1
<b>2. General policy</b>	6
2.1 International collaboration	6
2.1.1 Collaboration with international organizations and agencies	6
2.1.2 Pharmacopoeial Discussion Group	7
2.1.3 International Conference on Harmonisation	7
2.1.4 International Conference of Drug Regulatory Authorities	8
2.2 Cross-cutting pharmaceuticals – quality assurance issues	8
2.2.1 Biological standardization	8
2.2.2 Essential medicines	9
2.2.3 Herbal and complementary medicines	9
2.2.4 Working group meeting on substandard/spurious/falsely-labelled/falsified/ counterfeit medical products	10
<b>3. Quality control – specifications and tests</b>	10
3.1 <i>The International Pharmacopoeia</i>	10
3.1.1 Fourth edition update	10
3.1.2 Outreach with stakeholders	11
3.1.3 Annotated work plan	11
3.1.4 Monograph development	12
3.2 Specifications for medicines, including children's medicines	12
3.2.1 Medicines for HIV and related conditions	12
3.2.2 Antimalarial medicines	13
3.2.3 Antituberculosis medicines	14
3.2.4 Anti-infectives	14
3.2.5 Other medicines	15
3.2.6 Other paediatrics	16
3.3 General monographs for dosage forms and associated method texts	16
3.3.1 Pharmacopoeial Discussion Group-harmonized general texts	16
3.3.2 Uniformity of content single-dose preparations	21
3.3.3 General monograph on tablets	23
3.4 Preface, general notices and supplementary information sections of <i>The International Pharmacopoeia</i>	24
<b>4. Quality control – International Reference Materials (International Chemical Reference Substances and Infrared Reference Spectra)</b>	25
4.1 Update on International Chemical Reference Substances	25
4.1.1 Report on activities of the host organization related to International Chemical Reference Substances	25
4.1.2 Frequently asked questions about collaborative trials	26
4.1.3 Annual report on International Chemical Reference Substances 2010	26
4.1.4 Lumefantrine for system suitability testing	27
4.1.5 Bacterial endotoxin	27

<b>5.</b>	<b>Quality control – national laboratories</b>	27
5.1	External Quality Assurance Assessment Scheme	27
<b>6.</b>	<b>Quality assurance – good manufacturing practices</b>	29
6.1	WHO good manufacturing practices: water for pharmaceutical use	29
<b>7.</b>	<b>Quality assurance – new approaches</b>	29
7.1	WHO guidelines on quality risk management	29
<b>8.</b>	<b>Quality assurance – distribution and trade of pharmaceuticals</b>	29
8.1	WHO Certification Scheme on the quality of pharmaceutical products moving in international commerce	29
8.2	Update on Joint FIP/WHO guidelines on good pharmacy practice: standards for quality of pharmacy services	30
<b>9.</b>	<b>Prequalification of priority essential medicines including active pharmaceutical ingredients</b>	30
9.1	Update on the Prequalification of Medicines Programme managed by WHO	30
<b>10.</b>	<b>Prequalification of quality control laboratories</b>	31
10.1	Update on the prequalification of quality control laboratories	31
10.2	Update on the surveys of the quality of medicines	32
<b>11.</b>	<b>Regulatory guidance</b>	32
11.1	Policy on oseltamivir and zanamivir	32
11.2	Assessment criteria for blood regulatory systems	33
11.3	Pharmaceutical development for multisource (generic) pharmaceutical products – points to consider	34
11.4	Guidelines on submission of documentation for a multisource (generic) finished pharmaceutical product: quality part	34
11.5	Development of paediatric medicines: points to consider in pharmaceutical formulation	35
11.6	Provision by health-care professionals of patient-specific preparations for children that are not available as authorized products: points to consider	37
11.7	Quality requirements for artemisinin as a starting material in the production of antimalarial active pharmaceutical ingredients	38
11.8	Update on comparator products	39
<b>12.</b>	<b>Nomenclature, terminology and databases</b>	39
12.1	Quality assurance terminology	39
12.2	International Nonproprietary Names for pharmaceutical substances	40
<b>13.</b>	<b>Miscellaneous</b>	41
13.1	Brochures on the Expert Committee and on quality assurance of pharmaceuticals	41
13.2	Sampling procedures for monitoring of market situations	41
13.3	<i>Index of pharmacopoeias</i>	42
13.4	Collaboration with pharmacopoeias	42
<b>14.</b>	<b>Summary and recommendations</b>	43
	<b>Acknowledgements</b>	51

<b>Annex 1</b>	63
Development of monographs for <i>The International Pharmacopoeia</i>	
<b>Annex 2</b>	67
WHO good manufacturing practices: water for pharmaceutical use	
<b>Annex 3</b>	91
Pharmaceutical development of multisource (generic) pharmaceutical products - point to consider	
<b>Annex 4</b>	121
Guidelines on submission of documentation for a multisource (generic) finished pharmaceutical product for the WHO Prequalification of Medicines Programme: quality part	
<b>Annex 5</b>	197
Development of paediatric medicines: points to consider in formulation	
<b>Annex 6</b>	227
Recommendations for quality requirements for artemisinin as a starting material in the production of antimalarial active pharmaceutical ingredients	

# WHO Expert Committee on Specifications for Pharmaceutical Preparations

Geneva, 10–14 October 2011

## Members

Professor S.A. Bawazir, Head of Drug Sector and Vice-President, Saudi Food and Drug Authority, Riyadh, Saudi Arabia (*Chairperson*)

Mr A.C. da Costa Bezerra, Senior Pharmacist, Gerente-General de Inspecao e Controle de Medicamentos e Produtos, Agencia Nacional de Vigilancia Sanitaria – Brazilian Health Surveillance Agency, Brasilia, Brazil

Mr E. Wondemagegnehu Biwota, Addis Ababa, Ethiopia

Professor T.G. Dekker, Research Institute for Industrial Pharmacy, North-West University, Potchefstroom, South Africa

Professor J. Hoogmartens, Professor Emeritus, Laboratorium voor Farmaceutische Analyse, Leuven, Belgium

Professor S. Jin, Chief Expert for Pharmaceutical Products, National Institutes for Food and Drug Control, Beijing, People's Republic of China (*Co-Chairperson*)

Dr T. Kawanishi, Head, Division of Drugs, National Institute of Health Sciences, Tokyo, Japan (*Rapporteur*)

Professor H.G. Kristensen, Vedbaek, Denmark

Dr J.A. Molzon, Associate Director for International Programs, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD, USA (*Rapporteur*)

Ms C. Munyimba-Yeta, Director, Inspectorate and Licensing, Pharmaceutical Regulatory Agency, Lusaka, Zambia

Ms L. Slamet,<sup>1</sup> Deputy for Therapeutic Products, Narcotics, Psychotropic and Addictive Substance Control. National Agency of Drug and Food Control. Jakarta Pusat. Indonesia

预览已结束，完整报告链接和

<https://www.yunbaogao.cn/report/index/report>